These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 26763627)

  • 21. Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database.
    Sonawane KB; Cheng N; Hansen RA
    J Manag Care Spec Pharm; 2018 Jul; 24(7):682-690. PubMed ID: 29952714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A characterization and disproportionality analysis of medication error related adverse events reported to the FAERS database.
    Carnovale C; Mazhar F; Pozzi M; Gentili M; Clementi E; Radice S
    Expert Opin Drug Saf; 2018 Dec; 17(12):1161-1169. PubMed ID: 30451017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of the MedDRA hierarchy on pharmacovigilance data mining results.
    Pearson RK; Hauben M; Goldsmith DI; Gould AL; Madigan D; O'Hara DJ; Reisinger SJ; Hochberg AM
    Int J Med Inform; 2009 Dec; 78(12):e97-e103. PubMed ID: 19230751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucose homeostasis abnormalities associated with use of gatifloxacin.
    Frothingham R
    Clin Infect Dis; 2005 Nov; 41(9):1269-76. PubMed ID: 16206101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing fluoroquinolone-associated aortic aneurysm and dissection: Data mining of the public version of the FDA adverse event reporting system.
    Meng L; Huang J; Jia Y; Huang H; Qiu F; Sun S
    Int J Clin Pract; 2019 May; 73(5):e13331. PubMed ID: 30809871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse event profiles of platinum agents: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations.
    Sakaeda T; Kadoyama K; Okuno Y
    Int J Med Sci; 2011; 8(6):487-91. PubMed ID: 21897761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Standardizing drug adverse event reporting data.
    Wang L; Jiang G; Li D; Liu H
    Stud Health Technol Inform; 2013; 192():1101. PubMed ID: 23920875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Time-to-signal comparison for drug safety data-mining algorithms vs. traditional signaling criteria.
    Hochberg AM; Hauben M
    Clin Pharmacol Ther; 2009 Jun; 85(6):600-6. PubMed ID: 19322165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adverse event detection using the FDA post-marketing drug safety surveillance system: Cardiotoxicity associated with loperamide abuse and misuse.
    Swank KA; Wu E; Kortepeter C; McAninch J; Levin RL
    J Am Pharm Assoc (2003); 2017; 57(2S):S63-S67. PubMed ID: 28073687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.
    Haber P; Moro PL; McNeil MM; Lewis P; Woo EJ; Hughes H; Shimabukuro TT
    Vaccine; 2014 Nov; 32(48):6499-504. PubMed ID: 25258101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adverse event profile of tigecycline: data mining of the public version of the U.S. Food and Drug Administration adverse event reporting system.
    Kadoyama K; Sakaeda T; Tamon A; Okuno Y
    Biol Pharm Bull; 2012; 35(6):967-70. PubMed ID: 22687540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of benzonatate overdoses among adults and children from 1969-2010 by the United States Food and Drug Administration.
    McLawhorn MW; Goulding MR; Gill RK; Michele TM
    Pharmacotherapy; 2013 Jan; 33(1):38-43. PubMed ID: 23307543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potentially inappropriate concomitant medicine use with the selective COX-2 inhibitor celecoxib: Analysis and comparison of spontaneous adverse event reports from Australia, Canada and the USA.
    Baselyous Y; De Cocinis M; Ibrahim M; Kalra A; Yacoub R; Ahmed R
    Expert Opin Drug Saf; 2019 Mar; 18(3):153-161. PubMed ID: 30929580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topical bovine thrombin: a 21-year review of topical bovine thrombin spontaneous case safety reports submitted to FDA's Adverse Event Reporting System.
    Clark JA; Humphries JE; Crean S; Reynolds MW
    Pharmacoepidemiol Drug Saf; 2010 Feb; 19(2):107-14. PubMed ID: 20014051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dietary Supplement Adverse Event Report Data From the FDA Center for Food Safety and Applied Nutrition Adverse Event Reporting System (CAERS), 2004-2013.
    Timbo BB; Chirtel SJ; Ihrie J; Oladipo T; Velez-Suarez L; Brewer V; Mozersky R
    Ann Pharmacother; 2018 May; 52(5):431-438. PubMed ID: 29171279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug Safety Monitoring in Children: Performance of Signal Detection Algorithms and Impact of Age Stratification.
    Osokogu OU; Dodd C; Pacurariu A; Kaguelidou F; Weibel D; Sturkenboom MC
    Drug Saf; 2016 Sep; 39(9):873-81. PubMed ID: 27255487
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system.
    Sakaeda T; Kadoyama K; Okuno Y
    PLoS One; 2011; 6(12):e28124. PubMed ID: 22205938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system.
    Colman E; Szarfman A; Wyeth J; Mosholder A; Jillapalli D; Levine J; Avigan M
    Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1068-76. PubMed ID: 18821724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.
    McAdams M; Staffa J; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):229-39. PubMed ID: 18175291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.